 New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics NYSE:ADCT. The company raised 267.6 million through the sale of 14,082,475 of its common shares priced at 19.00 per share. Funds managed by New Ventures III and New Ventures Select have invested in ADCT since 2015. In just over a month, New Ventures has seen two portfolio companies complete successful public listings, the second being Royalty Pharma NASDAQ: RPRX. 